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CHAPTER 1
INTRODUCTION
Randomized trials are considered the gold standard in establishing the benefit of an
intervention. Systematic confounding is eliminated, and for Frequentist Inference,
randomization provides a means to accurately measure the uncertainty of an estimated
intervention effect. To varying degrees randomized trials cost resources including but
not limited to time, finances, and possibly volunteers who participate in a study. For
example, novel therapeutics approved by the Food and Drug Administration can often
be financially costly. Between 2015-2016 the Food and Drug Administration accepted
138 trials to approve 59 novel therapeutic drugs with median enrollment of 488 patients
(IQR, 230 – 740) and median cost per patient of $41,117 (IQR, $31,802 - $82,362)
(Moore et al., n.d.). An ideal trial expends just enough resources to draw a clear
clinical conclusion. This ideal motivates study design methods that (1) increase the
efficiency of a trial by increasing the balance of baseline covariates and (2) adaptively
monitor a trial until ruling out either clinically meaningful effects or trivial effects.
On average randomization removes systematic confounding, yet any single instance of
randomization may include at least some degree of imbalance on key baseline covariates.
In extreme instances, the most predictive baseline covariates of the outcome will be
randomized to a particular intervention arm. An unlucky randomization, one with
substantive imbalances between intervention arms on key baseline covariates, may
jeopardize the study. The study analysis would need to adjust for the imbalanced
baseline covariate(s) and in a manner sufficiently convincing to the scientific community.
Existing methods, called covariate-adjusted randomization, restrict randomization
by eliminating randomization instances with substantive imbalances on key baseline
covariates. As an important side-benefit, eliminating poor randomization instances
reduces the uncertainty in estimating the marginal intervention effect.
Stratified Block Randomization is the most commonly used method of covariate-
adjusted randomization. Participants of a trial are randomized within exact matches
of categorized baseline covariates. For example, a health study with participants of
multiple site may carry out Stratified Block Randomization by randomizing within
participants of the same site and health profile. As a limitation, continuous baseline
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covariates must be categorized. Categorization should generally be avoided. It may
suggest two participants to be scientific different despite only slight differences in their
continuous covariate. Also, the number of strata increases exponentially for adjusting
each additional categorized covariate. The number of strata may quickly overwhelm
the study sample size and counteract the intent to achieve baseline covariate balance.
An alternative method, known as Minimization, assigns participants to intervention
arms based on what would best reduce covariate imbalance. A variety of criteria
exist for measuring covariate imbalance; however, Minimization is often criticized for
eliminating randomization. Without randomization a study may become subject to a
systematic confounder, and there is not a model-free basis for quantifying uncertainty of
an estimated intervention effect. To introduce randomization, a trialist may randomize
a participant with increased probability to the intervention arm that better reduces
baseline covariate imbalance. This scheme is considered a Covariate-Adjusted Biased
Coin Randomization.
In a two-arm study, Matched Randomization (Greevy et al. 2004) randomizes the
intervention within pairs of participants who are most similar to each other. Matched
Randomization uses a distance matrix, such as Mahalanobis Distance, to find the set of
paired participants which overall have the greatest similarity. The matching-on-the-fly
algorithm allows for matching participants in studies with sequential enrollment, and in
simulation settings, it has been shown to be superior to Stratified Block Randomization
and Begg and Iglewicz Minimization (Kapelner and Krieger 2014). Participants are
matched if they are similar-enough relative to a pre-determined fixed threshold. The
threshold is based on an assumption that baseline covariates are normally distributed.
In Chapter 2, we extend matching-on-the-fly to use a dynamic threshold based
empirically on the given distribution of baseline covariates. We introduce re-matching
on the fly which allows matches to break and reform if a better set of matches comes
along throughout sequential enrollment. The REACH trial provides a framework, with
a sample size similar to the median sample size of recent studies approved by Food and
Drug Administration, for comparing our extensions with Block Randomization (i.e. no
covariate adjustment), Stratified Block Randomization, Biased-Coin Randomization,
and Minimization. Our method improves the baseline covariate balance and efficiency
in estimating treatment effects of existing methods. In certain settings – where we
condition on the most predictive baseline covariates and analyze the data with a
permutation-based inference – our method nearly doubles the effective sample size.
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Many study designs plan a sample size assuming the average performance of Block
Randomization (such as based on a t-test). In Chapter 2, we observe that a single
instance of Block Randomization may result in a non-trivial change in effective
sample size. Due to a single randomization instance, a study with a fixed number of
participants may have insufficient participants to detect a meaningful intervention.
There is a need to adaptively monitoring trials. (And, the need applies to accumulating
observation data).
With additional looks at the data, the probability of a false discovery increases.
To protect against false discoveries, some existing methods implore alpha-spending
techniques to ensure an overall type I error rate. While the principle of protecting
against a type I error rate is important, it is possible to find a statistically significant
effect yet of insufficient magnitude to be meaningful. In Chapter 3, we introduce
a new adaptive monitoring scheme using the second-generation p-value (Blume et
al. 2018, Blume:2019ea) that follows a study until ruling out meaningful effects or
ruling out trivial effects. That is, studies with non-trivial effects are both scientifically
meaningful and statistically significant.
The second generation p-value is a novel metric that establishes evidence regarding
an interval hypothesis (as compared to point null hypotheses in hypothesis testing).
The metric is easy to calculate as the overlap between the interval hypothesis and any
inferential interval – such as a confidence interval, credible interval, and support interval.
To adaptive monitor with the second generation p-value, the trialist establishes effects
deemed meaningful and effects deemed trivial. The second generation p-value raises
a flag when the evidence suggests a non-meaningful or non-trivial effect. As a proof
of principle, we demonstrate with REACH data our adaptive monitoring scheme
alongside adaptive monitoring using posterior probabilities to rule out meaningful or
trivial effects. For introducing and establishing our method, we make a simplifying
assumption that observing outcomes occur more quickly than enrollment.
Our adaptive monitoring design includes two features that improve the statistical
properties of the adaptive monitoring. First, we require a wait time before applying
monitoring rules. The wait time helps reduce early false discoveries which occur due to
additional looks. In the early phase of the study, the inferential interval is at greater
risk falsely ruling out trivial effects while the interval yet stabilizes. We also introduce
an affirmation step before stopping a trial. The affirmation step also helps reduce
false discoveries and reduces bias common to sequential monitoring designs.
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In Chapter 4, we address practical questions raised by in introducing adaptive moni-
toring with the second generation p-value. First, since study design attributes require
simulation, we provide a statistical package to increase the ease of implementation
when designing a study. Second, we make recommendations for how long to wait until
monitoring. Our recommendation ensures a type I error rate below α when drawing
inference on (1-α) intervals. Third, we provide suggestions for how long to monitor
when there is a lag between enrolling participants and observing outcomes.
Collectively, this body of work increases the efficiency and efficacy of randomized
clinical trials. We provide motivating examples and, in the case of adaptive monitoring,
statistical software to aid in the ease of implementation. The work is grounded in ran-
domized trials but has natural extensions into observation data which also emphasizes
the importance of baseline covariate balance and may benefit from accumulating data.
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CHAPTER 2
REMATCHING ON-THE-FLY: SEQUENTIAL REMATCHED RANDOMIZATION
AND A CASE FOR COVARIATE-ADJUSTED RANDOMIZATION
2.1 Introduction
Randomization eliminates systematic confounding and has been considered the “gold
standard” for clinical trials since World War II(Bothwell et al. 2016). And yet, the
most common approaches to randomization — Block and Stratified Randomization
— are just as old (Peirce and Jastrow 1884; Hill 1952; Armitage 1982). They are
limited in their ability to control the balance of baseline covariates. Covariate-adjusted
randomization, which includes Stratified Block Randomization reduces the uncertainty
in permutation-based inference by eliminating singular randomizations with poor
baseline covariate balance. It also increases the efficiency of model-based inference by
orthogonalizing baseline covariates with treatment assignment.
Balance is an important aim for clinical trials. Poor chance imbalances on key baseline
covariates can bring to question the face-validity of a randomized trial(Rosenberger
and Sverdlov 2008; Leyland-Jones 2003) especially when estimating the Population
Average Treatment Effect from the Sample Average Treatment Effect. Also, greater
covariate balance allows trialists to estimate heterogenous treatment effect across key
subgroups. Trials with secondary aims for personalizing medicine to key subgroups
rely upon overall covariate balance(Diener-West et al. 1989; Fu, Zhou, and Faries
2016). To reduce chance imbalances, the trialist may turn to covariate-adjusted
randomization (the focus of this paper) and / or fit a model that adjusts for chance
imbalances(Berchialla, Gregori, and Baldi 2018). With model-based inference, the
trialist must convince the clinical community their model is fully transparent and
sufficiently adequate(D. A. Freedman 2008a, 2008b; Lin 2013).
In single batch trials, where all participants or clusters are known before random-
ization, covariate-adjusted randomization randomizes within optimal partitions of
participants/clusters. Common and novel methods (and the imbalance measure they
optimize) include: Stratified Block Randomization (exact covariate matches)(Fisher
1935), Matched Randomization (overall sum of paired distances from a distance
matrix)(Greevy et al. 2004), Rerandomization (any imbalance measure though com-
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monly overall difference in covariate distances)(Morgan and Rubin 2012), Propensity-
Constrained Randomization (overall difference in propensity score variability)(Loux
2014), and Kernel Randomization (a linear or non-linear function of covariate differ-
ences) (Kallus and 2018 2018). Stratified Block Randomization randomizes within
exact matches of categorized baseline covariate levels whereas the other methods
randomize within near matches of continuous and categorical baseline covariates.
Exact matching is frequently limited in the number of matching baseline covariate
levels before overwhelming the sample size. Though still under development, some
theoretical and empirical evidence points to Kernel Randomization as the preferred
method for greatest balance(Kallus and 2018 2018).
With sequential enrollment, the full covariate pattern and optimal partitions are
unknown until the end of the study. Many of the single batch methods have exten-
sions for sequential enrollment yet lose some optimization compared to single batch
randomization. Minimization handles the sequential optimization problem by directly
allocating treatments to achieve optimal balance on specified imbalance criteria(Taves
1974). Randomization occurs when all treatment would have the same impact on
minimizing the imbalance criteria. Without randomization, Minimization schemes
may remain subject to systematic confounding. To relax deterministic allocation,
treatment may instead be allocated with a biased coin favoring the optimal treatment
per the imbalance criteria (Pocock and Simon 1975; Atkinson 1982). A common
covariate-adjusted biased coin method includes Urn Randomization(Wei and Lachin
1988). Sequential Matched Randomization and Sequential Rerandomization each
prespecifies a threshold to achieve a degree of overall balance(Kapelner and Krieger
2014; Zhou et al. 2018). In both cases the threshold is fixed without a clear optimal
threshold to be used in all situations.
This work achieves two purposes. First, it extends Sequential Matched Randomization
to recover some of the optimal balance achieved in single batch Matched Randomization.
The extensions allow (1) matches to rematch if a better mate enters the study, (2)
the threshold for optimal matches to adjust dynamically according to the number
of current matches and covariate distribution, and (3) participants to enroll/be
randomized in blocks. Second, through a two-arm case study (n = 512 participants) it
re-emphasizes the value of sequential covariate-adjusted methods, as a whole, compared
to Block Randomization. Sequential allocation methods considered include Block
Randomization, Stratified Block Randomization, Urn Randomization, Sequential
Matched Randomization, Atkinson’s Minimization with and without a biased coin,
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and Begg and Iglewicz’s Minimization. We do not include Sequential Rerandomization
as it requires determining an optimal threshold.
2.2 Notation
We denote a study as having enrolled i = 1, . . . , to N participants throughout
b = 1, . . . , to M batches of sequential enrollment. At the bth batch of enrolling
participants, denote the set of unmatched participants as Ub and the number of
participants in the set as ||Ub||. Let ||Rb|| be the number of expected remaining study
entrants. In general, covariate-adjusted randomizations are adjusted to p baseline
covariates in which a categorical covariate having q levels is coded by q − 1 dummy
variables.
In the simulation section, we generate j = 1, . . . , to 20,000 randomization schedules
for each allocation scheme.
2.3 Sequential Matching and Sequential Rematching
Sequential Matched Randomization uses the matching on-the-fly algorithm published
elsewhere(Kapelner and Krieger 2014) yet is worth summarizing to then extend. When
the first set of participants individually enroll, they are randomized to either treatment
or control and form a “reservoir” of participants who have been randomized but, as of
yet, have not matched with any other participant. Once a reservoir of pre-specified
size has built up, subsequent enrolling participants are compared to reservoir members
on baseline covariates using a distance matrix. The entering participant becomes
mates with their best reservoir match if they meet a pre-specified distance threshold of
similarity, and the entering participant receives the opposite treatment randomized to
their mate. Both are then excluded from the reservoir of potential mates. If, however,
the best reservoir match is not similar enough, the entering participant is randomized
and joins the reservoir awaiting a mate. By the end of the study, some participants
may not have found a mate, and treatment allocation may be imbalanced. Hereafter,
we’ll refer to the matching-on-the-fly algorithm as Sequential Matching.
Common practice uses Mahalanobis Distance and builds the initial reservoir to p+2
participants. This distance matrix reduces to euclidean distances when covariates are
independent, and p+2 observations are required before distances may be uniquely
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estimated. Current literature suggests setting the pre-specified threshold as a quantile
from the F(p, i - p) distribution(Kapelner and Krieger 2014); justification lies in the
fact that distances of normal covariates, when appropriately scaled, asymptotically
follow the F(p, i-p) distribution.
Throughout Sequential Matching, a participant may match before their better matching
mate enrolls. In this extension, we allow mates to break and rematch so long as
participants do not match within their treatment group. We refer to this re-matching
on-the-fly algorithm as Sequential Rematching and the randomization scheme as
Sequential Rematched Randomization.
2.4 Dynamic and Empirical Threshold
Sequential Matching, as is, uses a fixed quantile of the F-distribution; we formalize the
use of a dynamic threshold from an empirically-estimated distribution of randomly
matched distances. Lacking omniscience, an improperly selected fixed similarity
threshold may be problematic. An overly strict fixed threshold would yield no matches
and in turn may be no better than Complete Randomization. In contrast, an overly
relaxed threshold would degenerate to a block-two randomization scheme vulnerable
to subversion bias. Our proposed dynamic threshold reflects the chance of matching
an existing reservoir member out of all potential mates including those yet to enroll.
More formally, this is the proportion Qb where
Qb =
||Ub|| − 1
||Ub||+ ||Rb|| − 1 .
Although the number of possible mates in Rematching is the whole set of entrants, we
develop Qb for use with both Sequential Matching and Sequential Rematching.
Since not all covariates are normally distributed, we empirically estimate a reference
null distribution, F , as suggested in the matching on-the-fly paper(Kapelner and
Krieger 2014). To estimate F at the bth batch of enrolling participants (Fb), a random
set of i/2 matches are bootstrap sampled from the upper- (or lower-) triangle of the
distance matrix. The dynamic threshold is the averaged Qb percentile across bootstrap
samples of Fb. To achieve equal treatment allocation, the threshold for matches is
removed when the reservoir size is the same or less than the number of participants
left to enroll.
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Thresholdb =
Fˆ
−1
b (Qb) ||Ub|| < ||Rb||
best match(es) ||Ub|| ≥ ||Rb||
The threshold may also be removed to keep the reservoir size within a specified
maximum tolerated imbalance (Berger, Ivanova, and Deloria Knoll 2003).
2.5 Batch Entry
As is, Sequential Matching requires matching participants one at a time. However,
trials will allocate treatments in batches of various enrollment sizes. As when all
participants are known at the study outset, batch enrollment increases the chance of
finding a better mate. We extend Sequential Matching to allow for batches of multiple
participants using an “optimal” algorithm; mates are collectively determined based
upon the set of matches that yield the smallest sum of distances. The R package
nbpMatching easily finds optimal mates.
2.6 Case Study: REACH Trial
2.6.1 Context, Data Preparation, and Simulation Set up
The Rapid Education/Encouragement And Communications for Health (REACH)
randomized clinical trial(Nelson et al. 2018) provides text message-delivered diabetes
support for 12 months to help adults with type 2 diabetes improve glycemic control (as
measured by Hemoglobin A1c) and adhere to treatment medication. Participants are
randomized into one of three treatment arms with a 2:1:1 allocation ratio: enhanced
treatment as usual (a text message when study A1c results are available), frequent
diabetes self-care support text messages, and frequent diabetes self-care support text
messages with monthly phone coaching(Nelson et al. 2018). Now with complete
enrollment, 512 participants are completing follow-up assessments at 3, 6, 12, and 15
months post-baseline.
At baseline, clinical and demographics covariates were collected that may be associated
with subsequent Hemoglobin A1c, including site (Vanderbilt clinic versus Vanderbilt
University Medical Center primary care) baseline Hemoglobin A1c, age at enrollment,
gender, years of education, years of since diabetes diagnosis, race / ethnicity, medication
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type, income, and type of health insurance. Refer to supplement for the overall
distribution of each baseline covariate.
Randomization often occurred before all baseline covariates could be collected. Most
notably, baseline Hemoglobin A1c generally took additional time to process. In this
study, clinical coordinators enrolled participants and sent baseline data to the Data
Coordinating Center for weekly batch randomization via REDCap(Harris et al. 2009).
Though REACH follow-up continues, all baseline covariates have been obtained, and
we used baseline data alongside three-month Hemoglobin A1c values for simulations.
2.6.2 Simulations
With complete baseline covariates, we simulated the ability of various treatment
allocation schemes to achieve balance among baseline covariates among treatment
groups and compared their efficiency in estimating predicted three-month Hemoglobin
A1c values. Contender allocation schemes focused on Block Randomization, Stratified
Block Randomization, Urn(0, β) Randomization, single batch Matched Randomization,
Sequential Matched Randomization without the proposed extensions (similar to current
literature), Sequential Matched Randomization with the dynamic threshold, Sequential
Rematched Randomization with the dynamic threshold, Atkinson’s Minimization
Algorithm with a 2/3 biased coin (Efron 1971) and with deterministic allocation,
and Begg and Iglewicz Minimization. The minimization schemes aim to reduce the
standard error in estimating the treatment effect.
We carried out Block and Stratified Block Randomization using a block size of two. In
practice, blocks of size two are ill-advised for increasing the risk of subversion(Berger,
Ivanova, and Deloria Knoll 2003) but provide the greatest chance of equal treatment
allocation in simulations, especially when stratifying with many levels. As a point of
reference we included single batch Matched Randomization as the optimal matching
when all participants are known prior to randomization; and, to compare against
current Sequential Matched Randomization literature, we included Sequential Matched
Randomization with a fixed 20th percentile threshold of the F(p, i-p) distribution.
Atkinson’s Algorithm determines the most impactful treatment for reducing the esti-
mated treatment variability of a pre-specified model, which we specified as conditioning
on all categorical covariates and first through third degree polynomials of continuous
covariates. When there were fewer observations than model degrees of freedom, we
determined the optimal treatment for the pre-specified model using the generalized
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inverse(Senn, Anisimov, and Fedorov 2010).
For a realistic comparison to Stratified Block Randomization, each covariate-adjusted
allocation was adjusted to site and the most predictive baseline covariates of three-
month Hemoglobin A1c — baseline Hemoglobin A1c, medication type, and time since
diabetes diagnosis (see supplement for how these were determined). The number
of strata increase exponentially for each additional baseline covariate used to create
strata. While impractical for Stratified Block Randomization, each covariate-adjusted
allocation scheme also conditioned on all baseline covariates. Stratified Randomization,
Urn(0,β), and Begg and Iglewicz Minimization require categorized covariates; for
these schemes we conditioned on categorized derivations of baseline Hemoglobin A1c
(< 7.0%, 7.0%− 8.0%, 8.0%+), age (≤ 60, > 60), years of education (≤ 12, > 12), and
time since diabetes diagnosis (< 10,≥ 10 years).
Though REACH includes three treatment arms, we simplified to two equally allocated
arms — enhanced treatment as usual versus any intervention (henceforth called the
intervention arm). Missing baseline covariates and three-month Hemoglobin A1c were
multiply imputed using predictive meaning matching via the aregImpute function in the
R rms package; and single mean and mode imputation from the multiple imputations
was carried out to obtain a single complete dataset. Twenty thousand treatment
allocation schedules for each scheme were simulated on the single mean imputed dataset.
For each scheme’s generated 20,000 treatment schedules, we summarize with boxplots
the maximum (worst-case) and average absolute Standardized Mean Difference of all
baseline covariates. We also summarize end-of-study treatment allocation difference.
To compare the efficiency of different schemes, we generated outcomes assuming
a potential outcomes framework. Twenty thousand datasets were created where a
participant’s potential outcome under the control arm equaled predicted three-month
Hemoglobin A1c plus a random residual. The potential outcome of receiving the
intervention reflected a further reduction in predicted three-month Hemoglobin A1c by
0.5 (a clinically relevant improvement). By using predicted three-month Hemoglobin
A1c, we fixed the effects of baseline covariates. The only random components in
this framework are the treatment assignment and a random residual of predicted
three-month Hemoglobin A1c.
For the jth generated potential outcomes dataset, we obtained an observed study for
each allocation scheme using the scheme’s jth generated allocation schedule. From each
observed study, we calculated the permutation-based 95% Confidence Interval Width of
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the Sample Average Treatment Effect (difference in observed means) and model-based
95% Confidence Interval Width of the estimated treatment effect. The pre-specified
Ordinary Least Square Model adjusted for all baseline covariates with restricted cubic
splines on each continuous covariate and accounted for multiply imputed baseline
covariates. On the jth potential outcomes dataset, we also calculated the relative
width of each scheme’s Confidence Interval Width compared to the width from Block
Randomization. Block Randomization was carried out twice for each generated dataset
to compare one instance of Block Randomization to another. From this we calculated
the difference in effective sample size of each scheme relative to Block Randomization.
In the supplement, we further calculate the average size of the reservoir throughout
enrollment among matched randomization methods and the expected amount of
randomization occurring under each minimization scheme.
2.6.3 Simulation Results
By themselves, the set of most predictive covariates plus site, are highly predictive
of three-month Hemoglobin A1c (R2 = 0.43); adjusting for all baseline covariates is
slightly more predictive (R2 = 0.46). Atkinson’s Minimization only randomized the
first participant and is therefore excluded from comparisons regarding permutation-
based inference. For this reason, it is also difficult to draw conclusions regarding its
average performance balancing baseline covariates.
Balance of Covariates: As a point of reference and across simulations, Block Ran-
domization’s median worst-balanced baseline covariate had an absolute Standardized
Mean Difference of 0.21 (95% Percentile Confidence Interval: (0.13, 0.32); Figure 1)
and average absolute Standardized Mean Difference of 0.09 (0.06, 0.14) (Figure 2).
Adjusting randomization to the most predictive baseline covariates yielded only trivial
gain in lessoning the worst-case imbalance (maximum absolute Standardized Mean
Difference; Figure 1). Begg and Iglewicz Minimization performed best in reducing the
worst-case imbalance to 0.20 (0.12, 0.30). Income level and race / ethnicity remained
difficult covariates to balance (supplement).
Worst-case imbalance was better controlled when adjusting to all baseline covariates
(Figure 1). The proposed extensions each improved upon reducing the maximum
absolute Standardized Mean Difference, which was on median 0.16 (0.10, 0.25) for
Sequential Matched Randomization without any extensions (i.e., setting the matching
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threshold to the 20th percentile of the F(p, n-p) distribution). Adding the first
extensions – a dynamic empirically estimated threshold slightly reduced the maximum
absolute Standardized Mean Difference to 0.14 (0.09, 0.22). Further adding rematching
yielded a substantive reduction to 0.11 (0.07, 0.20); it nearly achieved the performance
single batched Matched Randomization (0.09 (0.05, 0.16)).
Overall baseline covariate imbalance (average absolute Standardized Mean Difference)
improved similarly and non-trivially across allocation schemes when adjusting random-
ization to most predictive baseline covariates (Figure 2). Again, greater improvement
occurred when adjusting to all baseline covariates. Adding the dynamic and em-
pirical threshold improved the performance of Sequential Matched Randomization,
and Sequential Rematched Randomization with the dynamic and empirical threshold
recovered much of the optimal performance of single batch Matched Randomization.
Improvement Upon Precision: When using Block Randomization, the median
permutation-based 95% Confidence Interval width of the estimated treatment effect
was 0.54 (0.50, 0.58) (Figure 3) and a fully-adjusted (all baseline covariates) ordinary
least squares 95% Confidence Interval width of 0.38 (0.37, 0.39) (Figure 4). Relative
to itself, the 95% Percentile Confidence Interval of change in effective sample size was
+/- 20 (Table 1).
The greatest precision gains to permutation-based inference came from schemes
adjusting for only the most predictive baseline covariates (Figure 3). An exception
was Begg and Iglewicz Minimization, which performed essentially the same on median
when adjusting for the most predictive versus all baseline covariates.
Excepting Urn Randomization, all other schemes that adjusted allocation to the most
predictive covariates achieved a Confidence Interval width of 0.43 or smaller, with
single batch Matched Randomization achieving on median the same efficiency as the
model-based efficiency under Block Randomization (Figure 3). Sequential Matched
Randomization with the dynamic and empirical threshold yielded a permutation-
based Confidence Interval width of 0.41 (0.38, 0.44), an improvement on Sequential
Matched Randomization without extensions 0.43 (0.40, 0.47). Sequential Rematched
Randomization (0.40 (0.36, 0.45)) further recovered some of the efficiency lost from
single batch Matched Randomization (0.38 (0.36, 0.41)). On median, Atkinson’s
Algorithm with a Biased Coin yielded the greatest permutation-based precision, nearly
doubling the effective sample size compared to Block Randomization. That is, Block
Randomization would have needed on median 436 (316, 572) additional participants to
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achieve the same amount of precision. The gains in effective sample size for Sequential
Rematched Randomization 416 (213, 663) was slightly less than when using Atkinson’s
Algorithm yet were still non-trivial.
When adjusting randomization to all baseline covariates, efficiency gains in
permutation-based inference were not as pronounced but still substantial (Figure
3). Sequential Rematched Randomization achieved a permutation-based Confidence
Interval Width of 0.46 (0.41, 0.51). Atkinson’s Minimization with a Biased Coin and
Begg and Iglewicz Minimization achieved the greatest permutation-based Confidence
Interval Width precision, 0.41 (0.40, 0.42) and 0.42 (0.38, 0.49) respectively. On
median, these were both superior to single batch Matched Randomization.
In contrast to permutation-based inference, schemes that adjusted to all baseline
covariates achieved the greatest gain in precision from a linear model adjusting to
all baseline covariates (Figure 4). While non-trivial, the gains relative to Block
Randomization were much less pronounced.
When adjusting to all baseline covariates, the best performing sequential enrollment
schemes included Sequential Rematched Randomization, Atkinson’s Algorithm with
and without a Biased Coin, and Begg and Iglewicz Minimization with Confidence
Interval widths of at most, on median, 0.376. Sequential Rematched Randomization
yielded an effective increase in sample size of 15 (-4, 37) above and beyond the
pre-specified model-based inference under Block Randomization.
End-of-Study Allocation Differences: Block Randomization, Sequential Matched Ran-
domization with a dynamic and empirical threshold, Sequential Rematched Random-
ization, and single batch Matched Randomization always achieved equal end-of-study
allocation (Figure 5). Begg and Iglewicz Minimization was close to achieving equal
end-of-study allocation. Atkinson’s Algorithm with a Biased Coin, which performed
well in achieving balance and efficiency ran a greater risk of ending the study with a
treatment imbalance 0.00 (-20.00, 20.00).
Randomization within Minimization: When adjusting Begg and Iglewicz Minimiza-
tion to the most predictive covariates, randomization occurred for roughly 20% of
participants (7.8% of participants when adjusting to all baseline covariates). See
supplement.
Reservoir Size: See supplement for the average reservoir size for Sequential Matched
and Rematched Randomization.
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2.7 Conclusions
We’ve introduced extensions to Sequential Matched Randomization that recover much
of the optimality lost from single batch Matched Randomization due to sequential
entry of participants. These extensions include Sequential Rematched Randomization
with a dynamic and empirical threshold and the ability to randomize participants in
enrollment blocks. Further, our case study re-emphasizes (Ciolino et al. 2011) the
value of covariate-adjusted randomization for increasing overall covariate balance and
efficiency estimating the Population Average Treatment Effect. The precision of the
permutation-based Sample Average Treatment Effect estimator achieved nearly the
same efficiency as model-based inference estimating the treatment effect.
Our work is consistent with other findings that there is a balance / efficiency trade-off
in choosing which covariates to adjust randomization(Kallus and 2018 2018; Atkinson
1999). Arguments can be made to prioritize balance, especially when investigating
important subgroups and when the strength of relationships between baseline covariates
and the outcome are unknown. And, arguments are made for prioritizing efficiency
especially when chance imbalances may be adjusted with a model (Medicine and 1999
1999). Weighted distance measures can allow an investigator to prioritize certain
covariates over others when determining matches and therefore balance(Greevy Jr. et
al. 2012).
In introducing Sequential Rematching, we add to a class of look-back allocation
schemes. Though participants have matched, their baseline covariates may yet be
updated or used again to increase covariate balance and precision. Also in this class are
Minimization schemes with and without a biased coin and Sequential Rerandomization.
Such schemes are beneficial when some baseline covariates are not initially available
at the time of randomization as was the case with Baseline Hemoglobin A1c in the
REACH trial.
In this case study, Begg and Iglewicz Minimization performed frequently among
the top performing Sequential allocation schemes and provided equal randomization
to, on average, roughly 20% of participants (7% when adjust randomization to all
baseline covariates). This provides some reassurance against systematic confounding.
Minimization is powerful from a study design perspective, and randomization is critical
for eliminating systematic confounding. This work begs the question, what is the
extent of randomization necessary to sufficiently reduce systematic confounding?
Many studies set sample size based on the average performance of block randomization
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(for example by basing of a t-test). This case study provides a cautionary reminder that
half of such studies will have a decreased effective sample size. Though all assumptions
and operations of a study may work perfectly, a non-adaptive trial may fail to find a
treatment effect due to chance alone. Covariate-adjusted randomization helps protect
against poor covariate imbalances and increases the chances of a sufficient effective
sample size all else the same.
Table 2.1: Median and 95 Percentile Confidence Interval of difference in effective sample size relative
to Block Randomization for each of 20,000 generated observed datasets. Two Block Randomization
sequences per generated observed dataset to allow comparing one instance of Block Randomization
to another. Schemes are ordered by efficiency gains for permutation-based inference.
Permutation Estimate Adjusted Model Estimate
Covariate-
Adjustment
Scheme Relative
Efficiency
Effective
Change in N
Relative
Efficiency
Effective
Change in N
None Block 1.000 0 (-19, 20) 1.000 0 (-23, 23)
Stratified 1.067 71 (6, 141) 1.002 2 (-20, 25)
Urn 1.104 112 (44, 183) 1.004 4 (-18, 27)
Seq Matched (20p) 1.112 122 (35, 225) 1.006 6 (-15, 29)
Seq Matched 1.119 129 (37, 242) 1.010 10 (-10, 32)
Seq Rematched 1.187 209 (62, 385) 1.014 15 (-4, 37)
Matched (Single Batch) 1.215 244 (128,
388)
1.016 16 (-3, 38)
Min SE (BI, Assign) 1.277 323 (109,
537)
1.016 16 (-3, 39)
Min SE (Atk, 2/3 prob) 1.326 388 (278,
508)
1.018 19 (1, 40)
All Baseline
Covariates
Min SE (Atk, Assign) N/A N/A 1.018 19 (4, 39)
Urn 1.139 152 (79, 229) 1.002 2 (-20, 25)
Seq Matched (20p) 1.244 280 (156,
431)
1.004 4 (-18, 27)
Min SE (BI, Assign) 1.263 305 (128,
518)
1.006 6 (-16, 29)
Stratified 1.275 321 (189,
484)
1.005 5 (-17, 28)
Seq Matched 1.308 363 (222,
539)
1.006 6 (-16, 28)
Seq Rematched 1.347 416 (213,
663)
1.008 8 (-13, 31)
Min SE (Atk, 2/3 Prob) 1.361 436 (316,
572)
1.007 7 (-15, 30)
Matched (Single Batch) 1.408 503 (331,
711)
1.010 10 (-12, 32)
Site and Most
Predictive
Baseline
Covariates
Min SE (Atk, Assign) N/A N/A 1.001 1 (-13, 20)
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Figure 2.1: Boxplot of the maximum absolute Standardized Mean Difference among all baseline
covariates for each of 20,000 simulated allocation sequences per allocation scheme. Matched-based
Randomization schemes are shaded in blue. Seq Matched (20p) is Sequential Matching before
applying proposed extensions; it uses a fixed 20th percentile of the F(p, i-p) distribution. Min
SE schemes are Minimization schemes proposed by Atkinson and Begg and Iglewicz to reduce the
standard error of a pre-specified Ordinary Least Squares Model. Min SE (Atk, 2/3 Prob) uses a 2/3
biased coin to randomize to the favorable arm under Atkinson’s Minimization.
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Figure 2.2: Boxplot of the average absolute Standardized Mean Difference among all baseline
covariates for each of 20,000 simulated allocation sequences per allocation scheme.
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Figure 2.3: Boxplot of the permutation-based 95% Confidence Interval Width estimating the Sample
Average Treatment Effect for each of 20,000 simulated observed datasets. Observed outcomes were
generated as the predicted three-month Hemoglobin A1c plus a treatment effect (if allocated to
treatment) and a random residual. The horizontal line in red is the median treatment effect Confidence
Interval Width under the pre-specified Ordinary Least Square model and Block Randomization (See
Figure 4).
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Figure 2.4: Boxplot of the model-based 95% Confidence Interval Width estimating the Sample Average
Treatment Effect, adjusted for all baseline covariates, for each of 20,000 simulated observed datasets.
The Ordinarly Least Squares (OLS) model was pre-specified to include all baseline covariates with
restricted cubic splines on each continuous outcome and accounted for multiple imputations.
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Figure 2.5: Boxplot of the difference in end-of-study treatment allocation for each of 20,000 simulated
allocation sequences per allocation scheme.
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CHAPTER 3
ADAPTIVE MONITORING USING SECOND GENERATION P-VALUES
3.1 Introduction
Conclusive clinical trials either rule out clinically trivial or clinically actionable treat-
ment effects. Like driving blind, this is a hard ideal to achieve without adaptive
monitoring. The costs of ending too soon, when resources and knowledge were available
otherwise, can be extraordinary (Pocock and Stone 2016b). On the other hand, a
significant yet non-clinically actionable study can also be costly (Pocock and Stone
2016a). For these reasons, and to the extent possible, investigators turn to adaptive
monitoring designs because the sample size is “not too big, not too small, but just
right (Broglio, Connor, and Berry 2014).” To this we add the imperative: to the point
of being clinically conclusive.
Unlike many study design aspects, clinical relevance is not an unknown assumption.
A-priori scientific relevance informs which treatment effects are trivially null effects
and which are clinically actionable enough to change clinical practice. Most sample
size estimates already incorporate the latter into the study design. Though some
study designs rule out a set of trivially null effects (Kruschke 2013; Hobbs and Carlin
2008; Freedman, Lowe, and Macaskill 1984), more common practice is to test for any
difference from the point null.
Trivial effects surround the point null and include, in the least, indistinguishable
treatment effects due to rounding error (Blume et al. 2018). They may also include
clinically irrelevant changes in a biomarker. This set of effects has many names
including but not limited to Indifference Zone and Region of Practical Equivalence
(Blume et al. 2018; Kruschke 2013); we call this set of effects the Trivial Zone.
Switching from a point null to interval null carries intuitive clinical interpretation and
endows a study with desirable statistical benefits.
Interval null hypotheses reduce family-wise type I error rates (Blume et al. 2018;
Kruschke 2013). False discoveries most frequently occur closest to the point null
hypothesis, and an interval null provides a stricter rejection criteria buffer that
eliminates many false discoveries. For the same reason, the interval null provides a
22
natural type I error adjustment for multiple looks / comparisons. Inferential approaches
to evaluating interval hypotheses include Bayesian, Likelihood, and second-generation
p-value inference. For any estimated interval (i.e. confidence interval, credible interval,
support interval, etc.), the second-generation p-value draws conclusions from how
much of the interval overlaps an interval hypothesis (Blume et al. 2018, 2019).
Many Bayesian adaptive trial designs incorporate interval null hypotheses (Freedman,
Lowe, and Macaskill 1984; Berry et al. 2010; Hobbs and Carlin 2008; Kruschke 2013),
and we develop an analogous Second Generation p-value adaptive design. The rest of
the paper follows as: establishing a-priori clinically relevant guideposts, introducing
the second generation p-value, adaptively monitoring with with the second generation
p-value, comparing the second generation p-value and Bayesian adaptive monitoring
with the REACH clinical trial data, and drawing final conclusions.
3.2 Clinically Relevant Guideposts
In a two-sided study, four boundaries provide clinical guideposts. Highly actionable
treatment effects are of a magnitude of at least of δE for benefit or of δH for harm.
Trivial treatment effects are between δTE and δTH and encompass the point null
(Figure 1). The remaining effects are moderately actionable; moderate treatment
benefits are between δTE and δE and moderate treatment harms are between δTH and
δH . In any study, the implementation of an intervention takes into account secondary
measures such as side effects, costs, etc.. Hence, a highly actionable effect is likely to
outweigh the off-setting benefits / costs. A moderately actionable effect has greater
equipoise with offsetting benefits / costs.A one sided study omits δH and δTH to focus
only on δTE and δE.
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Figure 3.1: Clinically relevant guideposts are determined during study design, based on scientific
context, and ought to be incorporated into the final study inference. In a one-sided study (left figure),
the clinical guideposts create the regions: no more than trivial effect, moderately actionable effect,
and highly actionable effect. In a two-sided study (right figure), three regions are created: trivial
effects, moderately actionable effects, and highly actionable effects.
A similar set of clinical guideposts, the Region of Equivalence, uses only two bound-
aries(Freedman, Lowe, and Macaskill 1984; Hobbs and Carlin 2008). Treatment effects
outside the Region of Equivalence deem the novel intervention as either clinically
superior or inferior to the standard of care. Under certain conditions (a one-sided
study with a buffer around the point null), these guideposts match the one-sided
guideposts we propose. The Trivial Zone is necessary to rule out effects trivial to
the point null and receive the benefits of an interval null such as reducing the False
Discovery Probability.
Setting a-priori clinical guideposts brings transparency to the study design. Most
study designs already incorporate δE when determining an adequate study sample
size. Yet, in many instances, end trial inference does not incorporate δE (or other
clinical guidepost decisions). For example, without knowing δE, none of a confidence,
credible, or support interval inform original study design intentions.
Excellent references are available for helping establish clinical guideposts (Freedman,
Lowe, and Macaskill 1984; Spiegelhalter, Freedman, and Parmar 1994; Kruschke 2018;
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Blume et al. 2018).
3.3 Second Generation p-value
An inferential metric, the second-generation p-value indicates when the data are
compatible with the alternative hypothesis, the Trivial Zone null hypothesis, or when
the data are inconclusive (Blume et al. 2018, @Blume:2019ea). More generally, it
may be used for any interval hypothesis. The second-generation p-value calculates the
overlap between an interval I (any interval including but not limited to a confidence,
credible, support interval, etc.) and the set of effects ∆H in the hypothesis H. The
interval includes [a, b] where a and b are real numbers such that a < b, and the length
of the interval is b - a and denoted |I |. The overlap between the interval and the set
∆H is |I ⋂∆H |. The second generation p-value is then calculated as
pH =
|I ⋂∆H |
|I| ×max
{ |I|
2|∆H | , 1
}
.
The multiplicative factor, max
{ |I|
2|∆H | , 1
}
, provides a small sample size correction –
setting pH to 0.5 when an interval overwhelms ∆H by at least twice the length. For a
Trivial Zone null hypothesis T, trivially null effects are ruled out when the pT = 0
whereas non-trivial effects are ruled out when pT = 1. The data are inconclusive when
0 < pT < 1.
Based on the four clinical guideposts, we define and focus on a Highly Actionable
Hypothesis, HA, and Trivial Hypothesis, T .
• Hypothesis HA: The treatment effect lies within a Region of Clinically Highly
Actionable Effects ∆HA = (−∞, δH ] ∪ [δE,∞) for a two-sided study and [δE,∞)
for a one-sided study where a positive benefit is beneficial. Where a negative
effect is beneficial, the one-sided study sets ∆HA = (−∞, δE].
• Hypothesis T : The treatment effect lies within a Region of Clinically Trivial
Effects ∆T = [δTH , δTE] for a two-sided study. In a one-sided study where a
positive effect is beneficial, ∆T = (∞, δTE] and is called a Region of At Most
Clinically Trivial Effects. The bounds are mirrored when a negative effect is
benificial.
Neither of these two hypotheses include moderately actionable treatment effects.
When applied to the four clinical guideposts, nine conclusions may be drawn from the
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second-generation p-value and the Regions of Clinically Highly Actionable Effects and
Clinically Trivial Effects (Figure 2). To motivate our adaptive monitoring design, we
reduce to three conclusions:
• When pHA = 0, the treatment effect is not clinically highly actionable.
• When pT = 0, the treatment effect is not trivial different from the point null.
• Otherwise, the treatment effect is inconclusive
Again, the interpretation of these regions closely relate to the interpretations of the
Region of Equivalence. They match exactly when in the case of a one-sided study with
a Trivial Zone around the point null.
Figure 3.2: Final study inference ought to incorporate a-priori clinical guideposts. The second
generation p-value draws inference based on hypothesized sets of treatment effects. We focus on two
sets of hypotheses that form the Region of Clinically Trivial Effects and the Region of Clinically
Highly Actionable Effects. (This figure focuses on two-sided studies yet similar conclusions are drawn
for one-sided studies). With the two sets of hypotheses, the second-generation p-value can rule
out trivial effects (the top four conclusions), rule out non-highly actionable effects (the middle five
conclusions), or declare the study yet inconclusive. Confidence intervals that correspond to a p-value
close to but not exceeding 0.05 would be declared inconclusive.
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3.4 Adaptive Monitoring Rules / Guidance
A study implements the following rules for adaptive monitoring with the second-
generation p-value:
• Design: Investigators a-priori determine the four clinical guideposts (two guide-
posts in the case of a one-sided study).
• Wait to Monitor: Enroll B participants before applying monitoring.
• Monitor: Calculate the second-generation p-value using an inferential interval
of choice. Raise an alert when pHA = 0 or pT = 0. Continue monitoring until
affirming the same alert (i.e. that again pHA = 0 or pT = 0) K participants later.
• Stop: Stop once affirming an alert or at the end of resources.
• Report: Report only the interval at stopping.
Finding the appropriate B and K is done through simulations in the study design
stage; both help protect against type I errors and bias. Chapter 3 provides practical
guidance for determining B and K. Type I errors more commonly occur early in
adaptive monitoring while estimated statistics are yet unstable, and they may occur
randomly in the discrete Brownian motion of the Monitoring Interval. Bias is inherent
in all adaptive monitoring schemes that stop at the first instance an alert is raised.
Requiring K participants to affirm an alert allows regression to the true treatment
effect and improves the reported interval’s coverage rate. To draw emphasis, we call
intervals used in the monitoring phase Monitoring Intervals as they are not to be
interpreted.
When the true effect is moderately actionable, the study may stop for concluding the
effect to be either not-trivial or not-highly actionable. This may bring consertnation;
however, it is an important study design feature. Without a region of clinically
moderately actionable effects, a highly actionable effect would border trivial effects
and have a 50-50 chance of stopping for being actionable or trivial. A study that stops
for concluding a non-trivial effect may include moderately actionable effects in the
inferential interval. And similarly, moderately actionable effects may be included in
inferential intervals when stopping to conclude a non-actionable effect. This behavior
reflects the greater degree of equipoise between the moderately actionable effects and
the off-setting harms/benefits.
Moderately actionable effects have a greater chance of raising conflicting alerts – for
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example to raise an alert for a non-trivial effect then K participants later alert for a
non-highly actionable effect. For this reason, we require the affirmation alert to be
the same as the alert it affirms. Only the final interval’s operating characteristics are
relevant.
With only adapting the monitoring rules, the remaining rules apply to monitoring
with Bayesian credible intervals. An alert for a non-highly actionable effect when
P(Treatment Effect /∈ ∆HA | Data) > 1 – αcriteria−not−actionable or for a non-trivial effect
when P(Treatment Effect /∈ ∆T | Data) > 1 – αcriteria−not−trivial. αcriteria−not−actionable
and αcriteria−not−trivial are study design tuning parameters based on simulations to
achieve a desired end of study type I error and power.
3.5 Adaptively Monitoring the REACH clinical trial
3.5.1 Context
The Rapid Education/Encouragement And Communications for Health (REACH)
randomized clinical trial (Nelson et al. 2018) is designed to help participants with
diabetes better manage glycemic control (as measured by Percent Hemoglobin A1c) and
adhere to medication. Patients randomized to the intervention receive text message-
delivered diabetes support for over 12 months. Now with complete enrollment, 512
participants are currently being followed up through 3, 6, 12, and 15 months.
In this population, lower Hemoglobin A1c reflects improved glycemic control. A
difference from baseline Hemoglobin A1c of +/- of 0.15 (median REACH baseline
Hemoglobin A1c of 8.20 [IQR of 7.20, 9.53]) is clinically trivial, whereas a decrease
of Hemoglobin A1c of 0.5 is highly actionable to the point of adopting this novel
intervention. While we anticipate the intervention to improve Hemoglobin A1c, we
designed the study to be two-sided. That is, δE = -0.50, δTE = -0.15, δTH = 0.15, and
δH = 0.50.
3.5.2 Simulation
The performance of adaptive monitoring using the second generation p-value and pos-
terior probabilities was observed from 20,000 bootstrap samples REACH participants.
With block two randomization (i.e. equal arm allocation every second participant)
half of the participants were randomized to receive the REACH intervention. For
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outcomes, we used three month predicted Hemoglobin A1c from an ordinary least
square model adjusting for baseline covariates including Hemoglobin A1c, age at
enrollment, gender, years of education, years of diabetes, race / ethnicity, medication
type, income, and type of insurance. All continuous baseline covariates flexibly allowed
for non-linear associations through restricted cubic splines. Predicted Hemoglobin
A1c changed by a treatment effect for those randomized to the REACH intervention.
We simulated multiple treatment effect settings {Treatment Effect: -1, -0.75, -0.50,
-0.375, -0.15, 0}. Only negative effects were investigated but by symmetry, increases
in Hemoglobin A1c of the same magnitude perform similarly. In these simulations we
assumed instantaneous outcomes.
Monitoring began after the 40th enrolled participant and continued every 20th partic-
ipant until either affirming an alert 40 participants later or until reaching the end of
resources (512 participants). For each second-generation p-value Monitoring Interval,
we fit a marginal ordinary least squares regression of outcome Hemoglobin A1c given
treatment assignment and obtained the 95% confidence interval for the treatment
effect. And, for adaptive monitoring using posterior probabilities, we used a Bayesian
alternative to the t-test: two-sample difference of means where the intervention group
mean, YI , and control group mean, YC , were both distributed t(µ, σ, ν) (Kruschke
2013).
For Bayesian priors, we set µ ~ N(y¯, 1 / φ-1(.9)) as a fairly flat prior centered on the
average mean Hemoglobin A1c of all observations with a 0.10 probability of observing
an absolute change in Hemoglobin A1c greater than 1. For a skeptical prior on µ,
we mixed the flat prior 1:1 with µ ~ N(y¯, 0.15 / φ-1(0.95)). We set σ ~ Gamma(sy
/ 1000, sy 1000) where sy was the non-pooled standard deviation of all Hemoglobin
A1c outcomes, and ν ~ Gamma(1/600, 30) + 1. The ν parameter places a prior on
the skewness of the data, and was chosen such that with the flat prior yielded group
means similar to raw means.
The two Bayesian adaptive designs (one with a flat and the other skeptical prior) were
calibrated to the second generation p-value design by finding the αcriteria−not−actionable =
αcriteria−not−trivial that achieve the same type I error given the true effect is zero and
that achieve the same probability of stopping for a not-trivial effect given the true
effect is -0.15 (the border of trivial effects). The later calibration was then used to
compare adaptive designs in terms of reasons for stopping, average trial sample size,
bias, and coverage of the reported interval. Operating characteristics are estimated
for given treatment effects. When allowing for distributional assumptions of observing
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the treatment effect, a correctly specified prior has zero bias.
3.5.3 Results
The flat and skeptical prior credible interval adaptive monitoring designs were cali-
brated to have the same type I error as adaptive monitoring with the second-generation
p-value (type I error = 0.033; Figure 3.3). While this was close to 0.05, the type I
error changes depending on the wait time until monitoring and the number of looks.
The flat and skeptical priors as specified both favor, at least some degree the null
hypothesis which is reflected as a decrease in power.
The probability of stopping for being not-trivial provides an adaptive monitoring analog
for a Type I error under an interval null hypothesis. When the true treatment effect
was truly -0.15 (i.e. the boundary of trivial effects), and when adaptively monitoring
with second-generation p-values, the probability of stopping for concluding not-trivial
was 0.063 (3.4). Posterior probability monitoring designs were again calibrated to this
same probability for this and the remaining figure results. The probability of stopping
for being not-trivial was slightly higher when monitoring using posterior probabilities
conditioned on the flat prior. However, for a clinically meaningful treatment effect of
-0.50, monitoring on posterior probabilities conditioned the flat had a higher probability
of stopping for concluding a non-highly-actionable effect than monitoring with the
second generation p-value. The two designs that monitored on credible intervals were
more likely to stop for concluding not-highly actionable effects than monitoring on the
second-generation p-value; this is consistent with both priors being at least slightly
favorable to the point null.
Trials monitored with the second-generation p-value using monitoring conifence in-
tervals lasted longest when the treatment effect was moderately-actionable (Figure
3.5). As posterior probabilities condition on priors more strongly favoring the null,
the longer trials occur for effects deemed moderately- to highly-actionable effects.
The bias was well mitigated when adaptively monitoring with the second generation
p-value and a posterior conditioned on a flat prior (Figure 3.6). The flat prior credible
interval pulls estimates toward the point null, which tended to slightly help when
the treatment effect was clinically meaningful and slightly hurt when the trivially
null. Neither the flat nor skeptical prior are biased if they are each reflective of the
true distribution of observing treatment effects. Coverage rates were increasingly
30
better when monitoring with posterior probabilities compared to the second generation
p-value. Of the treatment effects investigated, the worst coverage was 0.93 when
monitoring with the second generation p-value.
Figure 3.3: In the REACH target population, a decrease in Hemoglobin A1c reflects desireable
improvement in glycemic control. The power curve (i.e. the probability of rejecting the point null of
0), was estimated from 20,000 adaptive monitoring simulations when monitoring using the second
generation p-value (red circle) and posteriors conditioning on a flat prior (blue triangle) and skeptical
prior (purple square). The intervention was simulated to have an effect of -1 (highly beneficial), -0.75,
-0.50, -0.375, -0.15, to 0 effect (the point null). Bayesian adaptive monitoring designs were calibrated
to have the same type I error as the second generation p-value adaptive design.
Figure 3.4: In adaptive monitoring, a study can end in one of three states: concluding non-trivial
effect, concluding non-highly-actionable effect, or ending at the end of resources. Above are estimated
probabilities of ending in each of these states for each design and treatment effect. The probability of
concluding non-trivial is an interval null analog to power. The Bayesian adaptive monitoring designs
were calibrated to have the same probability of concluding a non-trivial effect as adaptive monitoring
with the second generation p-value. All following results are based off this calibration.
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Figure 3.5: Across simulations, the average time to stopping for the three adaptive designs is shown
above. In these simulations the earliest possible stopping time was the 80th participant. Monitoring
began at the 40th participant and continued at every 20th participant. Stopping required raising an
alert and affirming the alert 40 participants later. Moderately actionable treatment effects required
the greater sample size, while highly actionable and trivial effects required smaller sample sizes to
suggest stopping.
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Figure 3.6: At the study end, the final estimate and interval are reported. Across simulations, the bias
was well mitagated when adaptively monitoring using the second generation p-value and posterior
probability conditioned on a flat prior. A positive bias occurs when being pulled toward the null, as
happens with the skeptical prior.
Figure 3.7: At the study end, the final estimate and interval are reported. In these simulations,
a 95% confidence interval was reported when adaptively monitoring with the second-generation
p-value (though any other interval could have been used for monitoring and reporting). And, credible
intervals are reported for the Bayesian adaptive designs.
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3.6 Discussion
We developed an adaptive monitoring scheme, using the second generation p-value,
to follow studies until either ruling out trivially null or clinically highly actionable
treatment effects. Two major contributions come from this scheme: (1) the monitoring
scheme incorporates clinically relevant guideposts that may help trivially null and
clinically highly actionable studies stop quickly while still reaching a clear clinical
conclusion and (2) the easy-to-calculate second generation p-value allows an investigator
to adaptively monitor with their inferential interval of choice (including but not limited
to confidence intervals, credible intervals, and support intervals). While not explored
explicity in this paper, this design is well suited for following multiple outcomes and
following subgroups until they reach clear clinical conclusions.
In any adaptive monitoring implementation, the adoption of a novel agent depends
on multiple outcomes and reaching concluding an effect is highly actionable may not
mean the agent should be adopted. Data Safety Monitoring Boards are encouraged to
think of stopping rules more as guidelines when weighing the totality of evidence.
As seen in other similar designs, the use of an interval null decreases the false discovery
rate, making the results more reproducible (Blume et al. 2018; Kruschke 2013).
Incorporating clinical relevance into the inference brings study design transparency
that otherwise may get lost. For example, a confidence, credible, or support interval
alone do not inform of the targeted treatment effect when choosing a sample size.
With data from the REACH randomized clinical trial, we simulated adaptive moni-
toring using rules based on the second-generation p-value compared to rules based
on the posterior probabilities. Monitoring with the second-generation p-value and
posterior probabilities conditioned on a flat prior performed similarly in terms of
power, probability of stopping for efficacy, average sample size, bias, and reported
interval coverage. Monitoring using a flat prior credible interval had a slight edge
in these metrics but also a slightly worse probability of concluding highly-actionable
effects were not-highly actionable. The flat prior was not uniformly flat, it slightly
favored the point null.
All of the adaptive designs studied may be modified to achieve a desired type I error
and power. When adaptively monitoring with the second generation p-value, one may
change the wait time before monitoring and number of looks. We encourage clinical
guideposts to be anchored on clinical relevance and not change solely for the purpose
of achieving statistical properties. The same encouragement to not change anchors
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denoting clinical relevance hold true for monitoring with posterior probabilities.
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CHAPTER 4
THE SGPVAM PACKAGE AND PRACTICAL RECOMMENDATIONS FOR
ADAPTIVE MONITORING WITH THE SECOND GENERATION P-VALUE
4.1 Introduction
In Chapter 3 we present an adaptive monitoring scheme that follows studies until
evidence supports either a non-trivial or non-highly actionable treatment effect. The
design is very easy to implement. It can done by anyone who can think about the
clinical interpretation of possible effect sizes and calculate an interval estimate for their
effect, such as a credible, support, or confidence interval (CI) . However, estimating
the operating characteristics of a given study design is not as easy. Without tools to
assist them, it could be a barrier to implementation of the method.
In practice, the trialist will want to know the operating characteristics under the
following adaptive monitoring design features.
• Frequency of looks at the data, i.e. recalculate CI at every jth subject.
• Minimum precision requirement before applying monitoring rules, i.e. check
monitoring rules only if |CI| < w.
• Required observations between an alert and affirmation to stop, i.e. evaluate
stopping rule j*k subjects after alert.
• Anticipated maximum amount of data that could be collected, maxN, i.e. the
sample size at which the study will cease collection regardless of the stopping
rules.
• Lag time between enrolling a subject and observing their outcome measured
in the number of subjects recruited during the lag, i.e. m additional subjects
will be recruited in the time between one subject being recruited and that one
subject’s outcome being observed.
The trialist will mainly be looking for the point null type I error probability and power,
i.e. the probability of concluding an effect is non-trivial for a given true effect size.
They may also want some simple summary statistics for the potential sample sizes.
We hope to provide access to these and to a more rich set of operating characteristics.
Operating characteristics we can potentially estimate for a given set of design features
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include the following.
• Distribution of potential sample sizes.
• Point null type I error, when the point null is true, i.e. probability of excluding
the point null from the final interval estimate. Classical trialists will want
reassurance this is < 5%.
• Interval null type I error, when the point null is true, i.e. probability of excluding
the entire trivial zone from the final interval estimate. This will be less than or
equal to the point null type I error.
• Power vs the point null, i.e. probability the final interval estimate excludes the
point null for a given true effect size. This is akin to classical statistical power.
• Power vs the interval null, i.e. probability the final interval estimate excludes the
null zone for a given true effect size. This will be less than or equal to the point
null power, but is conceptually the preferable quantity. In better terms, this is
the probability of concluding the effect is non-trivial for given true effect sizes.
• Probability of concluding effect is non-highly actionable for given true effect
sizes.
• Probability of an inconclusive finding at the end of resources. Note a clinically
inconclusive finding is a possibility whenever maxN is finite and/or m > 0.
• Bias, MSE , and interval coverage probability from a frequentist perspective.
• False confirmation probability under a specified prior distribution. To address
these needs, we provide an R function, sgpvAM, that simulates the above
design operating characteristics for normal and binomial outcomes, and we offer
practical advice setting the minimum wait time (in terms of inferential interval
width) and the number of looks before affirming an alert.
4.2 sgpvAM Package
The sgpvAM package allows the user to obtain study design operating characteristics
under a variety of settings for adaptive monitoring using the second generation p-value.
4.2.1 Monte-Carlo Replicates
The user may use the sgpvAM function to generate Monte-Carlo replicates of outcomes
and intervention assignments along with an estimate of the effect and a lower- and
upper- interval bound; replicates are generated using parallel computing. Alternatively,
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the user may provide their own generated data together with an estimated effect
and interval bounds. When using the sgpvAM function, the user specifies the data
generation function (any of the r[dist] such as rnorm) along with arguments to the
function. Similarly, the user specifies effect generation. Currently, only fixed effects
have been thoroughly tested. However, by specifing a distribution for the effects, the
user may explore False Discovery Probabilities and other operating characteristics,
such as bias, dependent on distributional assumptions of the effect.
4.2.2 One- vs Two-Sided Hypotheses
Clinical Guideposts defining regions of Trivial and Highly Actionable Effects must be
provided though may be one- or two-sided. The point null must be within and not a
boundary of the Trivial Region. For general nomenclature, inputs to define the regions
are: deltaL2 (the Clinically Highly Actionable Boundary less than the point null),
deltaL1 (the Trivial Region Boundary less than the point null), deltaG1 (the Trivial
Region Boundary greater than the point null), and deltaG2 (the Clinically Highly
Actionable Boundary greater than the point null). See Chapter 3 for a thorough
discussion of these regions.
4.2.3 Tuning study parameters
To maximize performance of operating characteristics under a given sample size the
sgpvAM function allows the user to specify multiple wait time settings, frequency of
looks, and number of steps before affirming a stopping rule. (The wait time is the
time until the expected Margin of Error achieves a certain length or less). Here we
define the Margin of Error as one-half the interval width.
4.2.4 Operating characteristics under normal outcomes
After generating the operating characteristics under a fixed normal outcome, the user
may use the locationShift function to obtain operating characteristics under a range
of fixed treatment effects. The function uses the saved Monte-Carlo replicates and
adds to them if needed for additional monitoring.
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4.2.5 ECDF of sample size and bias
Once a study design has been selected based on average performance (sample size, bias,
and error probabilities), the user may use the ecdf.sgpv function to see the empirical
cumulative distribution across the Monte-Carlo replicates for sample size and bias
under a specific design. This provides an estimate of the probabilitiy a study does not
exceed a certain maximum sample size.
4.2.6 General suggestions
Computations may be time consuming. It is recommended to start with 1000 replicates
to get a general sense of average sample size and error probabilities under a variety of
investigated wait times and affirmation steps. Investigating many wait times increases
the computational burden. When generating data that allows for a location shift, it is
recommended to generate Monte-Carlo replicates in the (or one of the) mid point(s)
between the Clinically Trivial and Highly Actionable Regions. This is the region with
greatest expected sample size and reduces the burden of the locationShift function
generating additional data when necessary.
4.2.7 Inputs
mcData Previously generated data. Default (NULL) uses Monte-Carlo generation
inputs to generate new or additional data.
nreps Number of Monte-Carlo replicates to generate
waitWidths Wait time, in terms of Margin of Error (one half the confidence interval
width), before monitoring data.
dataGeneration Function (such as rnorm) to generate outcomes.
dataGenArgs Arguments for dataGeneration function. This includes, in the least,
‘n’ observations to generate. If ‘n’ is insufficient for unrestricted adaptive monitoring,
addtional data will be generated.
effectGeneration Function (such as rnorm) or fixed value to generate intervention
effect (theta).
effectGenArgs Arguments for effectGeneration function (if any)
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modelFit An existing or user-defined function to obtain intervals. Two existing
functions are provided: 1) lmCI which obtains a confidence interval from a linear
model and has class ‘normal’ indicating normal data and 2) lrCI obtains Wald
confidence interval from logistic regression model and has class ‘binomial’ indicating
binomial data.
pointNull Point null.
deltaL2 Clinical guidepost less than and furthest from point null.
deltaL1 Clinical guidepost less than and closest to point null.
deltaG1 Clinical guidepost greater than and closest to point null.
deltaG2 Clinical guidepost greater than and furthest from point null.
lookSteps The frequency data are observed (defaults to 1 – fully sequential).
kSteps Affirmation steps to consider range from 0 to maxAlertSteps by kSteps.
maxAlertSteps Maximum number of steps before affirming an alert.
maxN Total enrolled participants equals maxN observed participants plus lagOut-
comeN.
lagOutcomeN Total enrolled participants equals MaxN observed participants plus
lagOutcomeN. lagOutcomeN are number of observations enrolled but awaiting to
observe outcome.
monitoringIntervalLevel Traditional (1-alpha) used in monitoring intervals.
printProgress Prints when adding more data for Monte-Carlo replicates to have
sufficient observations to monitor until a conclusion. Defaults to TRUE.
outData Returns the Monte-Carlo generated data. This can result in an out object
with large memory. Yet, with location shift data, can be re-used to obtain operating
characteristics of shifted effects.
getECDF Returns the ECDF of sample size and bias for each wait width and number
of steps before affirming end of study.
cores Number of cores used in parallel computing. The default (NULL) does not run
on parallel cores.
fork Fork clustering, works on POSIX systems (Mac, Linux, Unix, BSD) and not
Windows. Defaults to TRUE.
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socket Socket clustering. Defaults to TRUE yet only applies if FORK = FALSE.
4.2.8 Return values
The sgpvAM function returns a list with three elements:
1. mcMonitoring – the mcReplicates when outData is TRUE,
2. mcEndOfStudy – operating characteristics on average and ECDF for each
combination of wait time and number of steps before affirming a stopping rule
3. inputs – Inputs in to the sgpv function
As supporting material for the package, we have developed an extensive vignette that
illustrates using sgpvAM to estimate and explore the impact of study design choices
on point null type I error, power for a range of true effect sizes, average sample sizes,
the distribution of possible sample sizes, and more. These include the types of figures
and calculations that will be of particular interest to the trialist. The full vignette
may be found at https://github.com/chipmanj/sgpvAM or by loading the sgpvAM
package and calling Vignette(package = “sgpvAM”, topic = “README”). Three of
the example figures are presented briefly below.
Figure 4.1 is a classical power curve which shows the probability the final CI will
exclude the point null at various true effect sizes. The power when the true effect
size is equal to the point null is the classical point null type I error probability. The
figure illustrates the impact of various wait times on the power curve. The second
generation p-value adaptive design allows for designing trials with finite and infinite
sample sizes in mind. We recommend presenting both. Figure 1 illustrates the infinite
sample size. Notice the point null type I error is bounded below 5% even when the
maximum sample size is theoretically infinite. Under this framework, a study that
stopped for reaching a maximum sample size could be restarted without concern of
controlling point null type I error.
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Figure 4.1: Power Curve across treatment effects for rejecting the point null in a one-sided study
when requiring different wait times before monitoring. The horizontal line is at 0.05 to indicate the
alpha level corresponding to the final reported confidence interval. The first vertical line denotes the
upper boundary of At Most Trivial Effects, and the second vertical line denotes the boundary of the
Highly Actionable Effects. The Wait times are the expected sample size for achieving a confidence
interval width. In this figure there is no restriction on sample size nor a lag in observing outcomes.
Figure 4.2 displays the impact of increasing the affirmation steps on the average
sample size. Increasing the affirmation steps has benefits in reducing bias, increasing
interval coverage probabilities, and increasing the stability of conclusions particularly
in the presence of a lag between recruitment and outcome observation. These benefits
come with an increase in average sample size, particularly in between the bounds of
the Trivial and Highly Actionable regions, i.e. where erroneous conclusions due to
stopping too early are most likely.
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Figure 4.2: The average sample size across treatment effects in a one-sided study when requiring
different wait times before monitoring. The first vertical line denotes the upper boundary of At Most
Trivial Effects, and the second vertical line denotes the boundary of the Highly Actionable Effects.
The Wait times are the expected sample size for achieving a confidence interval width. In this figure
there is no restriction on sample size nor a lag in observing outcomes.
Non-adaptive studies are typically designed a with high probability of an inconclusive
finding. Consider a non-adaptive study designed to have 80% power at a clinically
highly actionable effect size. Such a study will include the point null in its final
interval 20% of the time. It will include values from the null region with an even
higher probability. Although designed to only stop when a clinically highly actionable
conclusion has been found, second generation p-value adaptive monitored trials may
yield a clinically inconclusive finding if the trial has a fixed maximum sample size
and/or a lag between recruitment and outcome observation. This probability is highest
in between the bounds of the Trivial and Highly Actionable regions.
Figure 4.3 illustrates the control of this probability provided through increasing the
affirmation steps in the presence of a 50 subject lag time. Even with this large lag, a
relatively small affirmation step requirement bounds the probability of an inconclusive
finding below 20%.
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Figure 4.3: The probability of an inconclusive study (i.e. not ruling out Trivial or Highly Actionable
effects) when outcomes have a lag time until being observed relative to enrollment. The study stops
based upon drawing conclusions from observed data, yet after the remaining lagged outcomes (50
in this figure), the study would suggest more observations are needed to rule out Trivial or Highly
Actionable effects. The risk of being inconclusive is greatest in the midpoint between the Trivial and
Highly Actionable Regions (the boundary of the regions are respectively denoted by the two vertical
lines). Requiring fifty observations to affirm an alert reduces the worst-case risk of being inconclusive
to 20% in this setting.
4.3 Practical Recommendations
Of key importance to classical trialists is controlling point null type I error and
achieving a high probability of excluding the point null when the true effect size is
clinically highly actionable. To the medical researcher, key importance is to complete
the study with a clinically highly actionable finding. We show that focusing on the later
will achieve the former. When a study is not able to observe outcomes immediately,
care should be taken to reduce the risk of stopping and then being inconclusive after
observing the remaining observations.
To control error rates, one may change the clinical guideposts, reduce the number of
times monitoring the study, and/or increase the number of steps before affirming a
stopping rule. Ideally, the clinical guideposts chosen for their clinical interpretation.
We discourage altering them for the sake of operational characteristics. Instead, we
encourage optimizing operating characteristics through the waiting a period of time
before monitoring and requiring a number of observations to pass until affirming an
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alert to stop the study.
We consider various wait times based upon the expected confidence interval width under
an assumed outcome standard deviation. Twenty thousand Monte-Carlo replicates
of a study with standard normal outcomes are generated using the sgpvAM package
under five one-sided hypotheses settings and five symmetric two-sided hypotheses.
The settings reflect situations where (Setting 1) the Trivial and Highly Actionable
Effect bounds are both close to the point null of zero, (Settings 2-4) the Trivial Effect
bound is close to the null and the Highly Actionable Effect is far from the point null,
and (Setting 5) situations where the bound for Highly Actionable Effects is far from
the null and the bound for Trivial Effects is increasingly close to the Highly Actionable
Effect bound. These results generalize to normal outcomes with clinical guideposts
relative to the standard deviation.
For both one- and symmetric two-sided hypotheses, the probability of a type I error
is minimized by waiting until the Margin of Error equals the midpoint between the
Trivial and Highly Actionable Zones (Figure 4.4). For example, a one-sided study with
At Most Trivial Effects defined as (-∞, 0.1] and Highly Actionable Effects as [0.2, ∞)
reduces the probability of a type I error by waiting until the Margin of Error is 0.15.
In these simulations, the probability of a type I error remained less than or equal to
0.05 when waiting longer, until the Margin of Error equaled the positive boundary of
the Trivial Effects.
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Figure 4.4: Impact of different wait times upon type I error. Studies observe a minimum sample
size to achieve an expected minimum Margin of Error (half-width of a 95% confidence interval)
under an assumed outcome standard deviation of 1. Five one-sided (A) and five symmetric two-sided
(B) hypotheses are investigated. The upper bound for the Trivial Effect is denoted by the first
vertical line, and the second vertical line denotes the minimal highly actionable effect greater than
zero. Five combinations of effect size boundaries are shown. The lower bounds for the symmetric
two-sided hypotheses are not shown. For each minimum sample size / minimum CI width, operating
characteristics are provided with varying steps before affirming the stopping rule.
The following operating characteristics benefit from a longer wait time (i.e. waiting
until the Margin of Error is more narrow): power (Figure 4.5); an interval null
equivalent to type I error (Figure 4.8 and 8), power (Figure 4.7), and type II error
(Figure 4.9); and the probability of stopping for conclusive observed outcomes yet
becoming inconclusive after observing the remaining unobserved outcomes (Figure
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4.10). On the other hand, a shorter wait time yields smaller average sample sizes
(Figure 4.6). The gains in sample size diminishes once the wait time is the midpoint
between the Trivial and Highly Actionable Zones.
Figure 4.5: Impact of different wait times upon power, i.e. probability of rejecting the point null
when the true effect is equal to the boundary of the highly actionable effect zone, i.e. the vertical
line on the right. All other features of the figure mirror those of Figure 4.4.
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Figure 4.6: Impact of different wait times upon the average observed sample size given the true
treatment effect equals the average of the absolute trivial and highly actionable effect boundaries,
i.e. the middle of the two vertical lines. When the observation lag is zero, the observed sample size
equals the total sample size. All other features of the figure mirror those of Figure 4.4.
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Figure 4.7: Impact of different wait times upon the probability of concluding the treatment effect is
not trivial given the null true treatment. This an interval null analog to the type I error for a given
effect. All other features of the figure mirror those of Figure 4.4.
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Figure 4.8: Impact of different wait times upon the probability of concluding the treatment effect is
not trivial given the true effect equals the upper bound defining Trivial Effects. This is an interval
null analog to type I error for a given effect. This figure focuses on the boundary of the Trivial Effects
where the error probability is greatest. All other features of the figure mirror those of Figure 4.4.
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Figure 4.9: Impact of different wait times upon the probability of concluding the treatment effect
is not trivial given the true effect equals the boundary of the highly actionable effect zone, ie the
vertical line on the right. This is an interval null analog to power for a given effect. All other features
of the figure mirror those of Figure 4.4.
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Figure 4.10: Impact of different wait times upon the probability of being inconclusive after stopping for
observed outcomes and then observing remaining observations (50 observations in these simulations).
In this figure, the true effect is given to be the absolute average of the Trivial and Highly Actionable
regions (i.e. the mid point between the two regions); this is the treatment effect with the worst
probability of being inconclusive. Refer to figure 3 for the probability of being inconclusive across
the range of treatment effects under setting 3 (A). All other features of the figure 11 mirror those of
Figure 4.4.
On whole, this suggests waiting no longer than when the Margin of Error achieves
a length equal to this midpoint and may motivate waiting slightly longer (i.e. for
a smaller Margin of Error). In certain settings, when the boundary of the trivial
effects is close to half the boundary of the highly actionable boundary (settings 3
and 4), waiting for a slightly smaller Margin of Error has little added burden on the
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average sample size (Figure 4.6, compare settings 3 and 4 to setting 2). Across these
simulations, waiting for a slightly tighter Margin of Error balances well maximizing
operating characteristics without a substantive increase in average observed sample
size.
As a separate practical recommendation, we suggest increasing the number of affirma-
tion steps before stopping when observations are not immediately observable relative
to enrollment. For effects that are neither Trivial nor Highly Actionable, there’s a very
plausible chance the study ends conclusively for the outcomes observed yet becomes
inconclusive after observing the outcomes of remaining study observations (Figure
4.10). To reduce this risk, we recommend increasing the number of steps required to
affirm stopping rules.
4.4 Conclusion
We provide the sgpvAM package to provide greater ease of access to develop and
study the operating characteristics of adaptive monitoring with the second generation
p-value. Based on simulations of normally distributed data, we recommend waiting
until the expected confidence interval width is one quarter the absolute distance
between the Trivial and Highly Actionable Region boundaries. When outcomes do not
occur immediately, there is a risk of the study stopping then being inconclusive once
all observations are observed. This risk is reduced by requiring an increased number
of steps before affirming an alert to stop the study.
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CHAPTER 5
CONCLUSIONS
This body of work introduces study design methods and to improve the effective
sample size, allow for greater personalization of intervention to subgroups, and adap-
tively follow studies until reaching a clear clinical conclusion. Software and practical
recommendations are provided for developing adaptive monitoring study designs.
First, we provide novel extensions to Sequential Matched Randomization which
achieve greater covariate balance and efficiency than existing Sequential Matched
Randomization and traditional methods such as Stratified Block Randomization. A
dynamic and empirically-estimated matching threshold allows all patients to match
and relaxes an assumption that baseline covariates are normally distributed. We
allow matches to break and rematch if a better matches enrolls in the study. Under
our method, randomization-based inference achieves nearly the same efficiency as
fitting an adjusted linear model to adjust for baseline covariates. And, with greater
covariate balance, an investigator may better investigate the response of subgroups to
intervention.
Second, we introduce adaptive monitoring with the second-generation p-value which
allows for following a study until ruling out effects deemed trivial or until ruling out
effects highly actionable to change clinical practice. This grounds the clinical trial
not only on statistical significance but also clinical relevance, and can help reduce the
risk of a trial ending with inconclusive findings. We provide a case study through the
REACH, a Vanderbilt University Clinical Trial, aimed to help patients with diabetes
increase glycemic control and better adhere to medications.
Finally, we develop statistical software and provide practical recommendations for
designing an adaptive monitoring trial using the second generation p-value. The R
package sgpvAM simulates data to estimate operating characteristics for these trials;
the required simulation may be a barrier of entry to use this adaptive trial design.
We recommend a wait time before applying monitoring rules to control the classical
Type I error. When outcomes are not immediately observed relative to enrollment, we
recommend increasing the number of observations before affirming a stopping alert.
This reduces the risk of stopping based on observed observations then finding a study
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inconclusive when observing the remaining observations.
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